art4215
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 13, 2021 (NCT04991480)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNA polymerase thetaINHIBITOR
POLQ inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04991480 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2021 | Artios, Tennessee Oncology, PLLC, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Artios | For profit | 1 | 1 | 1 | 2021 |
| Tennessee Oncology, PLLC | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1